| Date Filed | Type | Description |
| 10/10/2023 |
SC 13G/A
| JANUS HENDERSON GROUP PLC reports a 15.4% stake in MADRIGAL PHARMACEUTICALS, INC. |
| 10/05/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 10% stake in Madrigal Pharmaceuticals, Inc. |
| 10/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 10/02/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/28/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2023 |
SC 13D/A
| BAKER BROS. ADVISORS LP reports a 8.4% stake in Madrigal Pharmaceuticals, Inc. |
| 08/08/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/17/2023 |
8-K
| Quarterly results |
| 07/12/2023 |
144
| Form 144 - Report of proposed sale of securities: |
| 06/30/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 05/09/2023 |
8-K
| Quarterly results |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/21/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 02/23/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/23/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/14/2023 |
SC 13G/A
| BAKER BROS. ADVISORS LP reports a 9% stake in MADRIGAL PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| ARMISTICE CAPITAL, LLC reports a 1.2% stake in MADRIGAL PHARMACEUTICALS, INC. |
| 02/14/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/14/2023 |
SC 13G/A
| Deep Track Capital, LP reports a 0% stake in Madrigal Pharmaceuticals, Inc. |
| 02/09/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of Tranche 2 Warrant Agreement, by and among Madrigal Pharmaceuticals, Inc. and Hercules Capital, Inc. and affiliates",
"Loan and Security Agreement, as amended by the First Amendment to Loan and Security Agreement, by and among Madrigal Pharmaceuticals, Inc., Canticle Pharmaceuticals, Inc., the several banks and other financial institutions or entities from time to time party thereto and Hercules Capital, Inc" |
|
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 01/10/2023 |
8-K
| Other Events Interactive Data |
| 12/23/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 12/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulat...|
Docs:
|
"Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock",
"Legal Opinion of Hogan Lovells US LLP",
"Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the institutional investors listed on the signature pages thereto",
"Amendment No. 2, to Securities Purchase Agreement, by and among Madrigal Pharmaceuticals, Inc. and the investors listed on the signature pages thereto",
"Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program" |
|
| 12/19/2022 |
8-K
| Quarterly results |
| 11/03/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/03/2022 |
8-K
| Quarterly results |
|